Study to Compare (COPD) Assessment Test in COPD Stage III and IV in a Prophylactic Treatment

Overview

The study will assess the treatment of patients with Chronic Obstructive Pulmonary Disease (COPD) stage III and IV who will self administer the AlphaCore stimulation three times a day over a course of 2 months. Patients will either receive an active AlphaCore device or a Sham device during these two months while not knowing which device they have been provided. At the end of the two months, all patients will be asked to continue in the study for another 2 months to self administer with the active AlphaCore device. Subjects will complete diaries at home on their breathing and quality of life and will return to the clinic monthly for assessment by the investigator.

Full Title of Study: “A Prospective, Single Site, Randomized, Controlled, Parallel Group Study in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Stage III and IV Using AlphaCore or Sham (Control, Not Active) as a Prophylactic Treatment”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Single (Participant)
  • Study Primary Completion Date: January 2013

Detailed Description

PERFORMANCE AND SAFETY VARIABLES:

The primary efficacy endpoint for this study is the total Chronic obstructive pulmonary disease (COPD) Assessment Test (CAT) score change from baseline to the 8 week follow-up period comparing the two device groups.

Secondary efficacy endpoints will be the mean difference from baseline to the 8 week follow-up for the following assessments: Medical Research Council (MRC) dyspnoea scale, 6 minutes walking test and Forced Expiratory Volume in one second (FEV1)

Safety Variables:

Each subject will be assessed throughout the study for Adverse Events and at the last visit (4 months) subjects will undergo another physical examination including vital signs and blood pressure.

Interventions

  • Device: AlphaCore device
    • Each study group will go under the same treatment regimen and assessments.

Arms, Groups and Cohorts

  • Active Comparator: Active AlphaCore device
    • AlphaCore active stimulation treatment
  • Sham Comparator: Sham AlphaCore device
    • AlphaCore sham device

Clinical Trial Outcome Measures

Primary Measures

  • Chronic Obstructive Pulmonary Disease Assessment Test (CAT) Scores (Quality of Life and Symptoms) Changes Within a Treatment Period and Comparison Between the Two Groups
    • Time Frame: 8 weeks
    • Chronic obstructive pulmonary disease Assessment Test (CAT) scores (Quality of life and symptoms) changes within a treatment period and comparison between the two groups. Eight (8) questions. The scale is rated from 0 to 5, min = 0, max = 5. Low rates = better, high rates = worse. Mean change in the period 8 weeks versus baseline.

Secondary Measures

  • Change in Borg Dyspnoea Scores
    • Time Frame: Baseline vs 8 weeks
    • Borg dyspnoea scale (Physical activity test): 0 – 11 (Not at all effected – Extremely effected) The result show the change between the the treatment groups from baseline to week 8
  • Change 6 Minutes Walking Test
    • Time Frame: Baseline vs 8 weeks
    • Six minutes walking test: Measure distance (meter) after 6 minutes walk. Change from Baseline between treatment groups
  • Change in Forced Expiratory Volume (FEV1)
    • Time Frame: Baseline vs 8 weeks
    • Forced Expiratory Volume (FEV1): Maximum volume that can be exhaled in the first second – after maximum inhalation. Change from baseline to week 8 between treatment groups
  • Change in EuroQol, 5 Questions and 3 Levels (EQ5D-3L)
    • Time Frame: Baseline vs 8 weeks
    • The EQ-5D-3L (EuroQoL 5 questions and 3 answering levels) during the run-in period will be compared with the EQ-5D-3L during the treatment period. And treatment period will be compared to open label. Rating of questions Level 1 no problems Level 2 some problems Level 3 Significant problems Worst case is 15 points and best case is 5 points using index
  • Number of Subjects With Adverse Events (AE)
    • Time Frame: Throughout the course of the study (baseline to the 4 month follow-up visit)
    • All AEs including but not limited to events reported by the subject or reported in response to an open question by the Clinical Investigator or member of this team, which fall into any of the above definitions must be recorded as an AE in the Case Report Form (CRF) and should include the following information. Brief description of the event (diagnosis) Start date (and time, if relevant) Stop date (and time, if relevant) (or resolution) Severity Action taken regarding the medical device Opinion on causality Seriousness Outcome
  • Change in Change in EuroQol, 5 Questions and 3 Levels (EQ-5D-3L), Visual Analogue Scale (VAS)
    • Time Frame: Baseline vs 8 weeks
    • Visual analogue scale (VAS) 0-100 where 0 is the worst imaginable health state and 100 the best imaginable health state

Participating in This Clinical Trial

Inclusion Criteria

  • Age 40-75 years
  • Diagnosed Chronic obstructive pulmonary disease(COPD) stage III and IV according to Global Initiative for chronic obstructive lung disease (GOLD) guideline
  • Forced expiratory volume in one second (FEV 1) < 50%
  • Forced expiratory volume in one second (FEV1/Forced expiratory vital capacity (FVC) < 70%
  • Signed informed consent form

Exclusion Criteria

  • Participation in other clinical trials (drug or medical device) 30 days prior to start of this study
  • Subject is unable to comply with the procedures if the protocol for the study or any other reason judged by the Investigator that could interfere with the study assessment or follow-up
  • Has an abscess or other infection or lesion (including lymphadenopathy) at the AlphaCore® treatment site.
  • Is currently implanted with an electrical and/or neurostimulator device, including but not limited to cardiac pacemaker, defibrillator, vagal neurostimulator, deep brain stimulator, spinal stimulator, bone growth stimulator, or cochlear implant.
  • Has a history of carotid endarterectomy or vascular neck surgery on the right side.
  • Right side or bilateral vagotomy
  • Has a recent or repeated history of syncope.
  • Has a recent or repeated history of seizures.
  • Pregnant or breast feeding women

Gender Eligibility: All

Minimum Age: 40 Years

Maximum Age: 75 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • ElectroCore INC
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Matthias John, MD, Principal Investigator, Praxis für Pneumologie am Asklepios Klinikum Uckermark

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.